for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AB Science SA

ABS.PA

Latest Trade

5.14EUR

Change

-0.01(-0.19%)

Volume

43,854

Today's Range

5.00

 - 

5.21

52 Week Range

3.10

 - 

5.65

As of on the Euronext Paris ∙ Minimum 15 minute delay

Latest Developments

AB Science Says Ab8939 Received Orphan Drug Designation For Acute Myeloid Leukemia

Nov 7 (Reuters) - AB Science SA <ABS.PA>::AB SCIENCE ANNOUNCES THAT AB8939 RECEIVES ORPHAN DRUG DESIGNATION FOR ACUTE MYELOID LEUKEMIA FROM FDA.

AB Science: AB8939 Receives Orphan Drug Designation For AML From FDA

Nov 7 (Reuters) - AB SCIENCE SA <ABS.PA>::REG-AB SCIENCE ANNOUNCES THAT AB8939 RECEIVES ORPHAN DRUG DESIGNATION FOR ACUTE MYELOID LEUKEMIA FROM FDA.ORPHAN DRUG STATUS ENTITLES COMPANY TO A 7-YEAR PERIOD OF MARKETING EXCLUSIVITY IN UNITED STATES FOR AB8939.ORPHAN DRUG STATUS ENABLES COMPANY TO APPLY FOR RESEARCH GRANT FUNDING FOR PHASE 1 AND PHASE 2 CLINICAL TRIALS AND TAX CREDITS FOR CERTAIN RESEARCH EXPENSES.

AB Science: 1st Presentation Of Preclinical Results For Compound AB8939

Nov 7 (Reuters) - AB SCIENCE SA <ABS.PA>::ANNOUNCED ON WEDNESDAY FIRST PRESENTATION OF PRECLINICAL RESULTS FOR COMPOUND AB8939 IN THE 61ST ASH ANNUAL MEETING ONLINE PROGRAM.IN VITRO PRECLINICAL STUDIES PROVIDE PROOF-OF-CONCEPT THAT AB8939 HAS BROAD APPLICABILITY AS POTENT ANTICANCER DRUG, PARTICULARLY IN TUMORS OF HEMATOPOIETIC AND LYMPHOID TISSUES, INCLUDING ACUTE MYELOID LEUKEMIA (AML).DATA SHOWS AB8939 IS HIGHLY POTENT PGP-INDEPENDENT, NEXT-GENERATION MICROTUBULE-DESTABILIZER DRUG FOR CANCER THERAPY, IN PARTICULAR, DIFFICULT TO TREAT HEMATOPOIETIC TUMORS SUCH AS RELAPSED/REFRACTORY AML.A FIRST IN HUMAN, PHASE 1 TRIAL EVALUATING AB8939 IN AML PATIENTS UNFIT TO RECEIVE INTENSIVE CHEMOTHERAPY IN SECOND AND THIRD-LINE WILL BE INITIATED IN 2020.THE EUROPEAN MEDICINE AGENCY (EMA) HAS VALIDATED THE CLINICAL DEVELOPMENT PROGRAM FOR AB8939 IN AML THROUGH A SCIENTIFIC ADVICE PROCEDURE.

AB Science Authorized To Start Phase 3 Confirmatory Study Of Masitinib

Oct 24 (Reuters) - AB Science SA <ABS.PA>::REG-AB SCIENCE GRANTED AUTHORIZATION TO INITIATE PHASE 3 CONFIRMATORY STUDY OF MASITINIB IN INDOLENT SYSTEMIC MASTOCYTOSIS.

AB Science Provides Update On Masitinib Programs Timelines

Oct 10 (Reuters) - AB SCIENCE SA <ABS.PA>::AB SCIENCE PROVIDES UPDATE ON MASITINIB PROGRAMS TIMELINES.COMPANY IS ON TRACK TO ANNOUNCE DATA IN SEVERE ASTHMA AND IN MS IN 4Q 2019.FINAL ANALYSIS OF SEVERE ASTHMA UNCONTROLLED WITH ORAL CORTICOSTEROIDS (STUDY AB07015) SEEN IN Q4 2019.FINAL ANALYSIS OF PROGRESSIVE PRIMARY AND SECONDARY MULTIPLE SCLEROSIS (STUDY AB07002) SEEN IN Q4 2019.FINAL ANALYSIS OF ALZHEIMER’S DISEASE (STUDY AB09004) SEEN IN Q4 2019/Q1 2020.FINAL ANALYSIS OF SEVERE ASTHMA UNCONTROLLED WITH INHALED CORTICOSTEROIDS (STUDY AB14001)SEEN IN Q2 2020.FINAL ANALYSIS OF PANCREATIC CANCER (STUDY AB12005) SEEN IN 2020.FINAL ANALYSIS OF METASTATIC PROSTATE CANCER (STUDY AB12003) SEEN IN 2020.

AB Science H1 Operating Loss Narrows To 10.6‍​ Million Euros

Sept 30 (Reuters) - AB SCIENCE SA <ABS.PA>::H1 NET REVENUE EUR 0.8‍​ MILLION VERSUS EUR 0.9 MILLION YEAR AGO.H1 OPERATING LOSS EUR 10.6‍​ MILLION VERSUS LOSS OF EUR 14.2 MILLION YEAR AGO.END-JUNE CASH POSITION EUR 2.7 MILLION VERSUS EUR 11.6 MILLION AT END-DECEMBER 2018.H1 NET LOSS EUR 13.0‍​ MILLION VERSUS LOSS OF EUR 11.1 MILLION YEAR AGO.

AB Science Raises EUR 10 Mln In Private Placement

Aug 20 (Reuters) - AB SCIENCE SA <ABS.PA>::ANNOUNCED ON MONDAY THE SUCCESS OF A PRIVATE PLACEMENT.EUR 10.0 MILLION RAISED THROUGH A PRIVATE PLACEMENT OF 2,463,054 NEW ORDINARY SHARES AT A PRICE OF EUR 4.06 .PRIVATE PLACEMENT WITH SUBSCRIPTION WARRANTS ATTACHED, GIVING RIGHT TO PURCHASE ADDITIONAL OF UP TO 1,231,527 SHARES AT EXERCISE PRICE OF EUR 5.50.WARRANTS SHALL BE EXERCISABLE WITHIN 5 YEARS FROM THEIR ISSUANCE AND NOT FREELY TRANSFERABLE .WARRANTS WILL NOT BE LISTED ON EURONEXT PARIS .IF ALL THE WARRANTS ARE EXERCISED, THE COMPANY WOULD RECEIVE AN ADDITIONAL EUR 6.7 MILLION OF PROCEEDS.

AB Science Announces The Publication Of The Positive Phase 2/3 Clinical Trial With Masitinib

July 8 (Reuters) - AB Science SA <ABS.PA>::Reg-AB SCIENCE ANNOUNCES THE PUBLICATION OF THE POSITIVE PHASE 2/3 CLINICAL TRIAL WITH MASITINIB IN ALS IN THE JOURNAL AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION.STUDY AB10015 REACHED ITS PRIMARY ENDPOINT AND SHOWED THAT MASITINIB AT 4.5 MG/KG/DAY IN COMBINATION WITH RILUZOLE WAS ABLE TO SIGNIFICANTLY (P-VALUE < 0.05) SLOW ALSFRS-R DECLINE BY 27% AS COMPARED WITH THE ACTIVE RILUZOLE CONTROL AT WEEK 48.KEY SECONDARY ENDPOINT, PFS (A TIME-TO-EVENT ANALYSIS, MEASURING THE EARLIEST EVENT BETWEEN DEATH AND FUNCTIONAL DECLINE OF AT LEAST 9 POINTS IN ALSFRS-R)5, WAS ALSO STATISTICALLY SIGNIFICANT (P<0.05), WITH A CLINICALLY MEANINGFUL 25% DELAY IN PROGRESSION (MEDIAN PFS OF 20.0 MONTHS FOR MASITINIB AS COMPARED TO 16.0 MONTHS FOR CONTROL).OTHER SECONDARY ENDPOINTS WERE ALSO SIGNIFICANT (P<0.05), with a 29% SLOWING OF DETERIORATION IN QUALITY-OFLIFE (ALSAQ-40) AND A 22% SLOWING OF DETERIORATION IN RESPIRATORY FUNCTION (FVC).SAFETY WAS ACCEPTABLE AND CONSISTENT WITH MASITINIB’S KNOWN RISK PROFILE.

AB Science: Validation Of AB8939 Clinical Development Plan Through Regulatory Authority Scientific Advice Procedure

July 4 (Reuters) - AB SCIENCE SA <ABS.PA>::AB SCIENCE : VALIDATION OF THE AB8939 CLINICAL DEVELOPMENT PLAN THROUGH REGULATORY AUTHORITY SCIENTIFIC ADVICE PROCEDURE.AB8939 IS A NEW GENERATION MICROTUBULE DESTABILIZER, 100% OWNED BY AB SCIENCE, THAT HAS PROMISING POTENTIAL IN ONCOLOGY.AB8939 IS 100 TIMES MORE POTENT THAN DOXORUBICIN (ADRIAMYCIN), WHICH IS A REFERENCE DRUG IN AML.AB8939 IS NOT DEACTIVATED BY MYELOPEROXIDASE ENZYME, WHICH IS AN ADVANTAGE OVER VINCA ALKALOIDS (VINCRISTINE OR VINBLASTINE).

AB Science: Positive Recommendation Of IDMC Following Interim Analysis Of Study AB12005

June 13 (Reuters) - AB SCIENCE SA <ABS.PA>::ANNOUNCED ON WEDNESDAY POSITIVE RECOMMENDATION OF THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC), FOLLOWING INTERIM ANALYSIS OF STUDY AB12005 IN THE FIRST-LINE TREATMENT OF PANCREATIC CANCER.STUDY AB12005 IS INTERNATIONAL, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 CONFIRMATORY STUDY OF MASITINIB IN FIRST-LINE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER PATIENTS WITH PAIN AT BASELINE OR TAKING OPIOIDS.PROBABILITY OF SUCCESS OF STUDY AB12005 IS ABOVE 80% IN THE SELECTED SUB-POPULATION.CO EXPECTS TO REPORT THE FINAL RESULTS FROM STUDY AB12005 IN 2020.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up